XP11.2 Translocation renal cell carcinoma: Clinical experience of Taipei Veterans General Hospital

Journal of the Chinese Medical Association

Volumn 74, Issue 11, 2011, Pages 500-504

  Hung, Chia Chen ^a   Pan, Chin Chen ^a,b   Lin, Chih Chieh ^a,b   Lin, Alex T L ^a,b   Chen, Kuang Kuo ^a,b   Chang, Yen Hwa ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Kidney; Renal cell carcinoma; Renal tumor; TFE3; Xp11.2 translocation

Indexed keywords

DNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E3; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; BONE METASTASIS; CANCER SIZE; CHROMOSOME TRANSLOCATION X; CHROMOSOME XP; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOARCHITECTURE; DISEASE COURSE; DNA SEQUENCE; FEMALE; FLANK PAIN; GENE FUSION; HEMATURIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDING; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; NEPHRECTOMY; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC THERAPY; TAIWAN; TREATMENT OUTCOME;

ADULT; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, X; FEMALE; HOSPITALS, VETERANS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAIWAN; TRANSLOCATION, GENETIC;

EID: 81455153992     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2011.09.005     Document Type: Article

References (18)

1. Hemesath T.J., Steingrimsson E., McGill G. Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 1994, 8:2770-2780.
2. Beckmann H., Su L.K., Kadesch T. TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer muE3 motif. Genes Dev 1990, 4:167-179.
3. Argani P., Antonescu C.R., Illei P.B., Lui M.Y., Timmons C.F., Newbury R., et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001, 159:179-192.
4. Argani P., Olgac S., Tickoo S.K., Goldfischer M., Moch H., Chan D.Y., et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007, 31:1149-1160.
5. Argani P., Lui M.Y., Couturier J., Bouvier R., Fournet J.C., Ladanyi M. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 2003, 22:5374-5378.
6. Tsuda M., Davis I.J., Argani P. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007, 67:919-929.
7. Tomlinson G.E., Nisen P.D., Timmons C.F., Schneider N.R. Cytogenetics of a renal cell carcinoma in a 17-month-old child: evidence for Xp11.2 as a recurring breakpoint. Cancer Genet Cytogenet 1991, 57:11-17.
8. Bruder E., Passera O., Harms D. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004, 28:1117-1132.
9. Ramphal R., Pappo A., Zielenska M., Grant R., Ngan B.Y. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. Am J Clin Pathol 2006, 126:349-364.
10. Selle B., Furtwangler R., Graf N., Kaatsch P., Bruder E., Leuschner I. Population-based study of renal cell carcinoma in children in Germany, 1980-2005: more frequently localized tumors and underlying disorders compared with adult counterparts. Cancer 2006, 107:2906-2914.
11. Argani P., Lal P., Hutchinson B., Lui M.Y., Reuter V.E., Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003, 27:750-761.
12. Argani P., Lae M., Hutchinson B. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 2005, 29:230-240.
13. Patard J.J., Leray E., Rioux-Leclercq N., Cindolo L., Ficarra V., Zisman A., et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005, 23:2763-2771.
14. Camparo P., Vasiliu V., Molinie V. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol 2008, 32:656-670.
15. Argani P., Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med 2005, 25:363-378.
16. Meyer P.N., Clark J.I., Flanigan R.C., Picken M.M. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am J Clin Pathol 2007, 128:70-79.
17. Malouf G.G., Camparo P., Oudard S., Schleiermacher G., Theodore C., Rustine A., et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC network. Ann Oncol 2010, 21:1834-1838.
18. Choueiri T.K., Lim Z.D., Hirsch M.S., Tamboli P., Jonasch E., McDermott D.F., et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010, 116:5219-5225.